Page 10 - Surface Oncology News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Surface oncology. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Surface Oncology Today - Breaking & Trending Today

FDA partially halts leukemia studies of Gilead cancer drug

BioPharma ....

Calistoga Pharmaceuticals , Boehringer Ingelheim , Drug Administration , Bristol Myers Squibb , Gilead Sciences , Dive Brief , Surface Oncology , Forty Seven , Kite Pharma , Arcus Biosciences , Clinical Trials ,

SHAREHOLDER ALERT: Weiss Law Investigates Surface Oncology, Inc.

SHAREHOLDER ALERT: Weiss Law Investigates Surface Oncology, Inc. ....

New York , United States , Joshua Rubin , Coherus Biosciences Inc , News Network , Surface Oncology Inc , Weiss Law , Surface Oncology , Coherus Biosciences ,

Vaccinex Reports Second Quarter 2023 Financial Results and Provides Corporate Update

Phase 1/2a SIGNAL-AD Study of Pepinemab in Alzheimer’s Disease Achieves Full Accrual Expect to Complete 12-months treatment in June, 2024 Promising Interim Results for KEYNOTE-B84 Phase 2 Trial.
-Today at 08:11 am- MarketScreener ....

United States , Albertd Friedberg , Vaccinex Rochester , John Mullaly , Maurice Zauderer , Exchange Commission , Alzheimer Drug Discovery Foundation , Platform Technology , Vaccinex Inc , Co Inc , University Of Rochester , Coherus Biosciences Inc , Merck Kga , Alzheimer Association , University Of Rochester Cancer Center , Lifesci Advisors , Pfizer Inc , Merck Sharp Dohme Corp , Merck Co , Moffitt Cancer Center , Development Expenses , Wilmot Cancer Institute , Merck Kgaa , Disease Achieves Full , Interim Results , Drug Discovery Foundation ,

Vaccinex Reports Second Quarter 2023 Financial Results and Provides Corporate Update - Vaccinex (NASDAQ:VCNX)

Phase 1/2a SIGNAL-AD Study of Pepinemab in Alzheimer's Disease Achieves Full Accrual Expect to Complete 12-months treatment in June, 2024 Promising Interim Results for KEYNOTE-B84 Phase 2 Trial in Head and Neck Cancer ....

United States , Vaccinex Rochester , Albertd Friedberg , John Mullaly , Maurice Zauderer , Alzheimer Association , Vaccinex Inc , Co Inc , Merck Co , Coherus Biosciences Inc , Exchange Commission , University Of Rochester Cancer Center , Lifesci Advisors , Merck Kgaa , University Of Rochester , Moffitt Cancer Center , Wilmot Cancer Institute , Pfizer Inc , Alzheimer Drug Discovery Foundation , Merck Kga , Development Expenses , Platform Technology , Merck Sharp Dohme Corp , Disease Achieves Full , Interim Results , Drug Discovery Foundation ,

Why Coherus BioSciences Stock Popped Today

The immuno-oncology leader delivered a strong second quarter. ....

Denny Lanfear , Coherus Biosciences , Surface Oncology ,